amantadin
ribavirin
alon
pair
combin
certain
experi
repeat
drug
incub
perform
repeat
harvest
viru
inocul
effect
viru
replic
measur
estim
cytopath
effect
titrat
infect
plaqu
assay
enhanc
antivir
activ
defin
decreas
viru
yield
compar
effect
either
drug
alon
enhanc
antivir
effect
seen
rimantadin
ribavirin
influenza
virus
effect
vari
accord
viru
strain
drug
concentr
viru
inoculum
amantadin
ribavirin
also
show
similar
enhanc
activ
specif
concentr
rimantadin
ribavirin
also
report
demonstr
enhanc
effect
influenza
b
data
shown
author
state
certain
drug
combin
extent
inhibit
viru
multipl
greater
addit
effect
singl
agent
suggest
synergi
increas
cytotox
ribavirin
concentr
time
higher
achiev
blood
follow
oral
administr
human
respons
experi
singl
agent
infect
ring
continu
expos
amantadin
ribavirin
mll
drug
incub
ring
inocul
viru
ten
time
determin
id
control
drug
toxic
includ
highest
concentr
experi
antivir
effect
assess
measur
preserv
ciliari
activ
control
baselin
activ
day
wherea
combin
synergist
delay
cytopath
effect
ring
durat
experi
mgl
peak
viru
product
suppress
log
combin
drug
significantli
greater
suppress
seen
singl
agent
infect
rel
small
inoculum
author
state
model
prophylaxi
infect
rimantadin
oseltamivir
zanamivir
peramivir
minut
incub
znv
plu
rimantadin
oc
plu
rimantadin
pmv
plu
rimantadin
drug
alon
concentr
nai
rimantadin
antivir
effect
assess
viru
yield
reduct
assay
cellbas
elisa
extracellular
viru
cellassoci
viru
assay
reduct
extracellular
viru
demonstr
addit
synergist
effect
cytotox
three
combin
maximum
synergi
anew
viru
infect
observ
rimantadin
pair
low
concentr
nai
combin
reduc
extracellular
yield
influenza
viru
synergist
contrast
drug
concentr
drug
low
concentr
high
concentr
yield
assay
cellassoci
viru
yield
may
underestim
efficaci
na
inhibitor
use
either
alon
combin
author
state
znvrimantadin
ocrimantadin
interact
similarli
inhibit
recoveri
extracellular
viru
mdck
cell
pmv
interact
rimantadin
differ
inhibit
extracellular
viru
cellassoci
viru
inhibit
antagonist
znvrimantadin
ocrimantadin
inhibit
recoveri
extracellular
viru
mdck
cell
pmvrimantadin
inhibit
extracellular
viru
murin
model
mice
challeng
ld
adamantanesuscept
aquailhong
viru
given
oral
oseltamivir
mgkgday
rimantadin
mgkgday
start
hour
viru
inocul
continu
total
day
administ
singli
oseltamivir
rimantadin
effect
prevent
death
mice
infect
high
dose
viru
delay
time
death
combin
significantli
increas
number
survivor
surviv
time
follow
lower
viral
inoculum
monotherapi
op
mgkgday
rimantadin
mgkgday
prevent
weight
loss
death
mice
combin
show
doserel
protect
two
inhibitor
effect
given
combin
given
monotherapi
across
rang
dose
data
effect
lung
titer
provid
amantadin
oseltamivir
ilyushina
na
et
al
antivir
re
vitro
resist
select
mdck
cell
infect
viru
ahong
viru
moi
pfucel
five
passag
except
second
pfucel
four
exposur
arm
strain
experi
amantadin
oc
yield
strain
significantli
reduc
p
cell
treat
combin
amantadin
low
dose
oc
sequenti
passag
presenc
singl
agent
associ
develop
substitut
replic
strain
complet
block
specif
concentr
oc
administ
combin
amantadin
act
addit
synergist
manner
sequenc
show
virus
genet
stabl
also
amantadin
passag
respect
combin
therapi
concentr
outlin
agent
control
drug
sensit
determin
plaqu
reduct
assay
cytotox
sialic
acid
receptorbind
na
enzym
inhibit
assay
perform
viral
rna
also
isol
amplifi
sequenc
amantadin
multipl
ha
mutat
oc
um
virus
bear
mutat
reduc
effici
sa
receptor
bind
decreas
sensit
nai
plaqu
reduct
assay
mutat
ha
na
seen
combin
therapi
passag
amantadin
oseltamivir
ilyushina
na
et
al
antivir
ther
mous
model
balbc
mice
intanas
innocul
mld
one
two
recombin
reverseengin
deriv
virus
one
amantadin
sensit
resist
prior
inocul
mice
commenc
amantadin
mgkgday
op
mgkgday
via
oral
gavag
day
amantadin
mgkgday
op
mgkgday
day
surviv
weight
chang
observ
viru
titr
harvest
organ
measur
egg
inocul
ha
na
gene
virus
day
lung
brain
combin
therapi
either
dose
amantadin
mgkgday
op
provid
dosedepend
protect
lethal
infect
amantadinesensit
viru
seen
singl
agent
compar
control
resist
viru
combin
therapi
produc
similar
result
op
alon
mutat
ha
na
seen
combin
therapi
addit
mutat
occur
monotherapi
lack
detect
amino
acid
substitut
virus
mice
treat
singl
agent
may
reflect
rel
short
cours
treatment
limit
sequenc
prophylact
cours
mgkgday
rimantadin
op
mgkgday
dose
ratio
oseltamivir
show
protect
index
pi
respect
mean
surviv
time
mst
day
contrast
monotherapi
use
dose
associ
pi
valu
rang
pi
mst
day
mst
respect
reduct
lung
patholog
seen
combin
therapi
given
treatment
higher
dosag
combin
therapi
mgkg
op
mgkg
rimantadin
result
pi
rang
mst
day
use
alon
dose
individu
compound
protect
vari
pi
mst
day
day
pb
control
compar
vehicl
individu
treatment
decreas
infecti
viral
titer
viral
pneumonia
prophylact
therapeut
cours
combin
oseltamivir
rimantadin
signific
protect
effect
mous
model
optim
dose
strategi
identifi
paramet
also
observ
combin
treatment
concentr
amantadin
oc
ribavirin
rang
log
dilut
drug
test
triplic
five
six
concentr
highest
concentr
drug
set
approxim
ec
drug
singl
agent
effect
concentr
ec
cytotox
concentr
tc
determin
drug
synergi
analysi
tcad
regimen
synergist
three
suscept
virus
multipl
concentr
three
drug
clinic
achiev
level
synergi
greater
tcad
doubl
combin
compon
agent
synergi
plot
tcad
show
concentrationdepend
increas
synergi
respect
amantadin
compon
ec
reduc
tcad
compar
ec
singl
agent
indic
drug
activ
lower
concentr
tcad
also
highli
synergist
drugresist
virus
amantadin
oc
shown
contribut
antivir
activ
tcad
regimen
amantadineand
oseltamivirresist
virus
respect
concentr
demonstr
activ
given
singl
agent
three
drug
appear
contribut
synergi
mechan
compon
agent
contribut
synergi
remain
unclear
howev
treatment
tcad
afford
surviv
mice
infect
either
virus
wherea
treatment
dual
singl
drug
regimen
result
surviv
given
monotherapi
antivir
activ
seen
amantadineresist
viru
amantadin
demonstr
dosedepend
protect
given
part
tcad
even
treatment
commenc
post
infect
suscept
viru
greatest
protect
weight
loss
observ
mice
treat
tcad
p
compar
doubl
combin
resist
viru
infect
greatest
protect
seen
tcad
signific
compar
amantadineop
p
opribavirin
p
doubl
combin
resist
viru
infect
dose
respons
slope
amantadin
given
tcad
significantli
greater
slope
given
singl
agent
viru
titr
emerg
resist
variant
report
vitro
test
pair
nai
perform
alongsid
separ
evalu
tcad
studi
evalu
ec
first
nai
combin
fix
concentr
second
nai
also
reveal
antivir
activ
drug
enhanc
combin
data
shown
taken
togeth
result
indic
absenc
synergist
effect
potenti
antagon
high
concentr
znv
oc
znv
pmv
vitro
mous
model
infect
mdck
cell
expos
ocpmv
day
balbc
mice
receiv
intranas
lethaldos
infect
ccid
mous
viru
antagonist
addit
synergist
effect
assess
use
comput
model
mgkgday
oral
opim
pmv
given
mice
interv
vitro
addit
narrow
region
synergi
found
viral
na
assay
combin
inhibitor
nm
signific
antagonist
synergist
interact
observ
across
rang
concentr
mice
twice
daili
op
mgkgday
combin
twice
daili
pmv
mgkgday
increas
surviv
significantli
protect
select
suboptim
dosag
combin
produc
addit
respons
pmv
oc
rimantadin
pk
paramet
show
effect
op
rimantadin
pk
pmv
effect
pmv
pk
oc
rimantadin
signific
ae
headach
treatment
arm
itt
analysi
rtpcr
confirm
influenza
primari
virolog
endpoint
achiev
op
znv
op
placebo
znv
placebo
mean
day
day
viral
load
decreas
respect
median
time
op
znv
less
effect
op
alon
significantli
effect
znv
alon
interferon
alon
significantli
affect
surviv
untreat
vs
treat
combin
amantadin
provid
addit
surviv
benefit
surviv
amantadin
combin
therapi
reduct
lung
infecti
viral
titr
interestingli
combin
amantadin
interferon
thymosin
improv
surviv
see
whole
anim
studi
follow
compar
protocol
lavrov
et
al
cell
cultur
studi
result
support
synergist
addit
effect
vivo
howev
interferon
requir
produc
surviv
benefit
thymosin
see
thymosin
alon
affect
surviv
surviv
unchang
combin
interferon
amantadin
three
agent
togeth
improv
surviv
decreas
lung
neither
interferon
thymosin
alon
effect
viral
titr
combin
three
appear
mark
effect
sinc
antivir
treatment
began
concurr
inocul
model
virus
treatment
group
receiv
receptor
agonist
prodrug
analog
aalr
via
intratrach
rout
infect
antivir
treatment
oseltamivir
start
one
day
infect
endpoint
surviv
day
aalr
alon
given
infect
improv
surviv
compar
control
oseltamivirtr
combin
oseltamivir
surviv
addit
benefit
oseltamivir
statist
signific
aalr
treatment
also
significantli
reduc
inflammatori
cytokin
bronchoalveolar
lavag
fluid
includ
aalr
treatment
initi
hour
infect
henc
studi
provid
mechanist
insight
littl
clinic
relev
consist
effect
antiinflammatori
treatment
oper
pathway
anim
model
sever
system
inflamm
howev
effect
seen
earli
treatment
antiinflammatori
drug
system
sepsi
gener
much
smaller
absent
treatment
given
therapeut
relev
timepoint
clinic
trial
sever
influenza
accord
stratifi
random
method
control
group
given
oseltamivir
experiment
group
given
oral
baicalin
oseltamivir
clinic
symptom
laboratori
paramet
cellular
immun
function
monitor
gender
age
compar
group
baselin
clinic
symptom
complic
includ
pneumonia
compar
combin
significantli
better
oseltamivir
monotherapi
improv
clinic
symptom
chest
radiographi
marker
cellular
immun
function
laboratori
indic
p
durat
viral
shed
significantli
shorter
experiment
group
compar
control
group
p
author
report
baicalin
combin
antivir
significantli
improv
clinic
cours
immun
patient
sever
influenza
influenza
definit
clinic
improv
chest
radiographyct
scan
chang
clearli
describ
data
chang
ldh
ck
crp
count
advers
effect
data
report
clinic
trial
total
ambulatori
patient
influenza
randomli
divid
four
group
receiv
oseltamivir
group
took
oseltamivir
lianhuaqingwen
capsul
group
b
treat
oseltamivir
banlangen
particl
group
c
lianhuaqingwen
capsul
group
clinic
virolog
outcom
third
fifth
day
among
four
group
compar
gender
age
compar
group
signific
differ
fever
among
group
rate
bodi
temperatur
normal
clinic
symptom
resolut
viral
clearanc
group
b
c
higher
group
p
paramet
similar
group
compar
group
b
c
p
efficaci
tend
better
group
b
oseltamivir
lianhuaqingwen
third
fifth
day
differ
signific
p
studi
confirm
earli
use
oseltamivir
shorten
durat
symptom
viral
shed
combin
therapi
lianhuaqingwen
oseltamivir
appear
warrant
studi
banlangen
improv
efficaci
random
procedur
blind
describ
paper
advers
effect
data
report
total
inpati
influenza
infect
divid
two
group
oseltamivir
oral
banlangen
control
group
oseltamivir
alon
fever
durat
clinic
symptom
length
stay
compar
group
two
group
compar
baselin
age
gender
symptom
wbc
p
resolut
fever
cough
sputum
sore
throat
better
combin
group
p
durat
hospit
significantli
shorter
combin
group
mean
sd
day
vs
ds
p
author
conclud
combin
therapi
banlangen
oseltamivir
better
oseltamivir
alon
random
procedur
blind
method
report
text
advers
effect
data
report
oseltamivir
tanreq
total
inpati
influenza
infect
divid
two
group
oseltamivir
intraven
tanreq
oseltamivir
alon
clinic
efficaci
compar
group
comparison
baselin
age
gender
symptom
done
group
clinic
efficaci
better
combin
group
p
side
effect
report
group
data
length
stay
report
author
conclud
combin
therapi
tanreq
oseltamivir
better
oseltamivir
alon
definit
clinic
efficaci
unclear
text
addit
limit
number
case
random
procedur
blind
method
describ
total
inpati
influenza
infect
divid
two
group
oseltamivir
iv
tanreq
oseltamivir
alon
clinic
efficaci
durat
hospit
comper
age
gender
symptom
compar
group
p
clinic
efficaci
length
stay
hospit
mean
sd
day
vs
better
combin
group
p
advers
effect
similar
group
author
report
combin
therapi
tanreq
oseltamivir
better
oseltamivir
alon
addit
limit
number
case
random
procedur
blind
method
describ
total
inpati
influenza
randomli
divid
oseltamivir
alon
group
patient
experiment
group
patient
receiv
oseltamivir
tanreq
inject
daili
treatment
last
day
overal
effect
key
symptom
physic
sign
radiolog
chang
compar
comparison
baselin
age
gender
symptom
done
group
overal
effect
combin
group
superior
control
group
improv
also
note
clinic
symptom
radiolog
chang
author
conclud
combin
therapi
tanreq
oseltamivir
better
oseltamivir
alon
definit
clinic
efficaci
random
procedur
blind
method
clearli
describ
advers
effect
data
report
oseltamivir
maingshiganyinqiao
san
wang
c
et
compar
control
confid
interv
ci
estim
median
time
fever
resolut
significantli
reduc
oseltamivir
ci
p
maxingshigan
yinqiaosan
ci
p
osletamivir
plu
maxingshigan
yinqiaosan
ci
p
oseltamivir
maxingshiganyinqiaosan
exhibit
borderlin
statist
signific
reduct
time
fever
resolut
compar
oseltamivir
ci
differ
declin
symptom
score
compar
intervent
control
two
patient
given
maxingshiganyinqiaosan
report
nausea
vomit
author
report
oseltamivir
maxingshigan
yinqiaosan
alon
combin
reduc
time
fever
resolut
patient
viru
infect
combin
exhibit
borderlin
statist
signific
reduct
time
fever
resolut
compar
oseltamivir
alon
limit
includ
studi
subject
young
mild
infect
miss
data
prohibit
definit
conclus
effect
viral
shed
abbrevi
oc
oseltamivir
carboxyl
op
oseltamivir
phosphat
pmv
peramivir
znv
zanamivir
ccid
median
cell
cultur
infecti
dose
ld
median
lethal
dose
mld
mous
median
lethal
dose
ec
effect
concentr
tc
cytotox
concentr
im
intramuscular
iv
intraven
iqr
interquartil
rang
rtpcr
revers
transcriptasepolymeras
chain
reaction
